Why “ Precision Health ” May Not Be the Precise Word

By DAVID SHAYWITZ, MD The appeal of precision medicine is the promise that we can understand disease with greater specificity and fashion treatments that are more individualized and more effective. A core tenet (or “central dogma,” as I wrote in 2015) of precision medicine is the idea that large disease categories – like type 2 diabetes – actually consist of multiple discernable subtypes, each with its own distinct characteristics and genetic drivers. As genetic and phenotypic research advances, the argument goes, diseases like “type 2 diabetes” will go the way of quaint descriptive diagnoses like “dropsy” (edema) and be replaced by more precisely defined subgroups, each ideally associated with a distinct therapy developed for that population. In 2015, this represented an intuitively appealing idea in search of robust supporting data (at least outside oncology). In 2017, this represents an intuitively appealing idea in search of robust supporting data (at least outside oncology). The gap between theory and data has troubled many researchers, and earlier this year, a pair of cardiologists from the Massachusetts General Hospital (MGH) and the Broad Institute, Sek Kathiresan and Amit V. Khera, wrote an important – and I’d suggest underappreciated – commentary in the journal Circulation that examined this very disconnect, through the lens of coronary artery disease (CAD). (Disclosures: I’m Chi...
Source: The Health Care Blog - Category: Consumer Health News Authors: Tags: OP-ED Uncategorized Broad Institute CAD Circulation Disease Categories Gimish Model of Disease Kathiresan Khera Massachussetts General Hospital Source Type: blogs

Related Links:

Condition:   Malignant Neoplasm Interventions:   Drug: Fentanyl Sublingual Spray;   Drug: Morphine;   Other: Physical Performance Testing;   Other: Placebo;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   D011471;   D064129;   D035683;   D009360;   D014408 Intervention:   Diagnostic Test: Periodic ARV7 and miRNA evaluation Sponsor:   Azienda Ospedaliero-Universitaria Careggi Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Arthritis, Rheumatoid Intervention:   Drug: Golimumab Sponsor:   Peking Union Medical College Hospital Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Hepatitis B Interventions:   Biological: Recombinant Hepatitis B (Bio Farma) Vaccine;   Biological: Recombinant Hepatitis B (Bio Farma) Vaccine® Sponsor:   PT Bio Farma Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Locally Advanced Colon Cancer Intervention:   Combination Product: CAPECITABINE AND OXALIPLATIN Sponsor:   Universidad de León Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Patients With Metastatic Colorectal Cancer Interventions:   Drug: Fluoropyrimidine;   Drug: Bevacizumab Sponsor:   Centre Hospitalier Universitaire Dijon Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Breast Cancer Interventions:   Drug: Avelumab;   Drug: Aspirin;   Drug: Lansoprazole Sponsors:   The Christie NHS Foundation Trust;   University of Manchester Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Nutrition;   Physical Activity Interventions:   Behavioral: Intervention Physical Activity;   Other: Usual Care Sponsors:   University of North Carolina, Chapel Hill;   University of Texas Completed
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Cystic Fibrosis Interventions:   Other: Autogenic drainage;   Device: SIMEOX + Autogenic drainage Sponsor:   Cliniques universitaires Saint-Luc- Université Catholique de Louvain Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
By DAVID SHAYWITZ, MD The appeal of precision medicine is the promise that we can understand disease with greater specificity and fashion treatments that are more individualized and more effective. A core tenet (or “central dogma,” as I wrote in 2015) of precision medicine is the idea that large disease categories – like type 2 diabetes – actually consist of multiple discernable subtypes, each with its own distinct characteristics and genetic drivers. As genetic and phenotypic research advances, the argument goes, diseases like “type 2 diabetes” will go the way of quaint descriptive...
Source: The Health Care Blog - Category: Consumer Health News Authors: Tags: Uncategorized Broad Institute CAD Circulation Disease Categories Gimish Model of Disease Kathiresan Khera Massachussetts General Hospital Source Type: blogs
More News: Arthritis | Blogging | Cancer | Cancer & Oncology | Cardiology | Cardiovascular | Cholesterol | Cystic Fibrosis | Diabetes | Endocrinology | Environmental Health | Fruit | Genetics | Health | Health Management | Heart | Hepatitis | Hepatitis C | Hospitals | Immunotherapy | Inflammatory Bowel Disease | Molecular Biology | Multiple Sclerosis | Psychiatry | Rheumatoid Arthritis | Rheumatology | Science | Statin Therapy | Training | Universities & Medical Training